	US 11,872,196 B2
	Use of cannabidiol in treatment of pulmonary hypertension
Ke Zhang, Beijing (CN); Xin Tan, Beijing (CN); Zhaohui Yu, Beijing (CN); and Xiangdong Li, Beijing (CN)
Assigned to DEYI PHARMARMACEUTICAL LTD., Kunming (CN)
Filed by DEYI PHARMARMACEUTICAL LTD., Kunming (CN)
Filed on Mar. 22, 2023, as Appl. No. 18/188,162.
Application 18/188,162 is a continuation of application No. 16/630,428, granted, now 11,666,542, previously published as PCT/CN2017/093367, filed on Jul. 18, 2017.
Prior Publication US 2023/0404941 A1, Dec. 21, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/05 (2006.01); A61P 9/12 (2006.01); A61P 11/00 (2006.01); A61K 31/191 (2006.01); A61K 31/192 (2006.01); A61K 31/4985 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/53 (2006.01); A61K 36/185 (2006.01); A61K 45/06 (2006.01)

CPC A61K 31/05 (2013.01) [A61K 31/191 (2013.01); A61K 31/192 (2013.01); A61K 31/4985 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/53 (2013.01); A61K 36/185 (2013.01); A61K 45/06 (2013.01); A61P 9/12 (2018.01); A61P 11/00 (2018.01)]

3 Claims

1. A method of treating pulmonary arterial hypertension in a human in need thereof consisting essentially of administering to the human in need thereof 0.1 mg/kg body weight −100 mg/kg body weight of isolated cannabidiol to effectively treat the pulmonary arterial hypertension in the human in need thereof.